References
- Nahmias A J, Roizman B. Infections with herpes-simplex viruses 1 and 2 (second of three parts). N Engl J Med 1973; 289: 719–25
- Dreesman G R, Burek J, Adam E, et al. Expression of her-pesvirus-induced antigens in human cervical cancer. Nature 1980; 283: 591–3
- McDougall J K, Crum C P, Fenoglio C M, Goldstein L C, Galloway D A. Herpesvirus-specific RNA and protein in carcinoma of the uterine cervix. Proc Natl Acad Sci USA 1982; 79: 3853–57
- Rapp F, Duff R. Transformation of hamster embryo fibroblasts by herpes simplex viruses type 1 and type 2. Cancer Res 1973; 33: 1527–34
- Poulsen H E, Thylor C W, Sobin L H. Histological typing of female genital tract tumours. World Health Organization, Geneva 1975
- Armitage P. Statistical methods in medical research. 4th ed. Blackwell Scientific Publications, Oxford 1977, chapter 16.2
- Fleiss J L. Statistical methods for rates and proportions. John Wiley & Sons, New York 1973
- Skinner G RB, Whitney J E, Hartley C. Prevalence of type-specific antibody against type 1 and type 2 herpes simplex virus in women with abnormal cervical cytology; evidence towards prepubertal vaccination of seronegative female subjects. Arch Virol 1977; 54: 211–21
- Vestergaard B F, Hornsleth A, Pedersen S N. Occurrence of herpes- and adenovirus antibodies in patients with carcinoma of the cervix uteri. Cancer 1972; 30: 68–74
- Burger M PM. Herpesvirussen en cervixcarcinoom; een sero-epidemiologisch onderzoek. University of Groningen, GroningenNetherlands 1979, Dissertation
- Syrjaˇnen K J. Human papillomavirus (HPV) infections of the female genital tract and their associations with in-traepithelial neoplasia and squamous cell carcinoma. Pathology Annual, S C Sommers, P P Rosen, R E Fechner. Appleton Century Crofts, Norwalk (Conn) 1986; vol. 21: 53–89
- zur Hausen H. Human genital cancer: synergism between two virus infections or synergism between a virus infection and initiating events?. Lancet 1982, ii: 1370–2
- Rola-Pleszczynski M. In vitro induction of human cell-mediated cytotoxicity directed against herpes simplex virus-infected cells. Kinetics in normal donors and patients with recurrent herpes labialis. J Clin Lab Immunol 1981; 6: 39–43
- Rola-Pleszczynski M, Lieu H. Natural cytotoxic cell activity linked to time of recurrence of herpes labialis. Clin Exp Immunol 1984; 59224–8
- Kirchner H, Schwenteck M, Northoff H, Schopf E. Defective in vitro lymphoproliferative responses to herpes simplex virus in patients with frequently recurring herpes infections during disease-free interval. Clin Immunol Immunopathol 1978; 11: 267–74
- Thong Y H, Vincent M M, Hensen S A, Fuccillo D A, Rola-Pleszczynski M, Bellanti J A. Depressed specific cell-mediated immunity to herpes simplex virus type 1 in patients with recurrent herpes labialis. Infect Immun 1975; 1276–80
- Centifanto Y M, Zam Z S, McNeill J I, Kaufman H E. Leucocyte migration inhibitory factor in HSV infections. Invest Ophthalmol Visual Sci 1978; 863–8
- Bloom B R, Rager-Zisman B. Cell-mediated immunity in viral infections. Viral immunology and immunopathology, A L Notkins. Academic Press, New York 1975; 113–36
- Allison A C. Interactions of antibodies, complement components and various cell types in immunity against viruses and pyogenic bacteria. Pansplant Rev 1974; 19: 3–55
- Blanden R V. T cell response to viral and bacterial infection. Pansplant Rev 1974; 19: 56–88
- Ross C AC, Tyrell W F. Possible prevention of bronchial carcinoma by recurrent herpes simplex. Lancet 1974, i: 871
- Naegeli O. Beobachtungen von antagonistischer Wirkung des Herpes simplex s. febrillis bei akuten und chronischen Infektionskrankheiten. Klin Wschr 1935; 14: 341–3